Connect Biopharma Holdings Ltd - Ordinary Shares, par value $0.000174 per share (CNTB) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2021 to Q4 2025

Type / Class
Equity / Ordinary Shares, par value $0.000174 per share
Symbol
CNTB on Nasdaq
Shares outstanding
55,803,824
Price per share
$2.82
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
1,288
Total reported value
$3,632
% of total 13F portfolios
0%
Share change
-294
Value change
-$829
Number of holders
1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Connect Biopharma Holdings Ltd - Ordinary Shares, par value $0.000174 per share (CNTB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Panacea Innovation Ltd 25% $13,950,000 13,950,000 Panacea Innovation Limited 21 Jul 2025
BioFortune Inc 11% $16,995,010 6,026,813 Wubin Pan 31 Dec 2025
Wei Zheng 9% -9% $14,144,506 -$1,442,571 5,015,960 -9.3% Zheng Wei 31 Dec 2025
Ikarian Capital, LLC 8.8% $13,910,809 4,933,086 Ikarian Capital, LLC 31 Dec 2025

As of 31 Dec 2025, 1 institutional investors reported holding 1,288 shares of Connect Biopharma Holdings Ltd - Ordinary Shares, par value $0.000174 per share (CNTB). This represents 0% of the company’s total 55,803,824 outstanding shares.

Institutional Holders of Connect Biopharma Holdings Ltd - Ordinary Shares, par value $0.000174 per share (CNTB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,288 $3,632 -$829 $2.82 1
2025 Q3 1,582 $2,389 -$2,397,515 $1.51 1
2025 Q2 2,444,820 $2,399,065 -$179,460 $0.98 17
2025 Q1 2,827,742 $1,555,037 -$242,900 $0.55 13
2024 Q4 3,181,027 $4,372,490 +$306,229 $1.38 14
2024 Q3 2,944,726 $4,229,340 +$101,251 $1.44 11
2024 Q2 2,976,236 $4,523,173 -$1,478,482 $1.52 12
2024 Q1 3,947,159 $6,867,831 -$3,787,306 $1.74 11
2023 Q4 7,118,656 $8,400,371 -$3,060,514 $1.18 14
2023 Q3 10,078,543 $8,221,166 -$60,098 $0.80 12
2023 Q2 10,358,458 $11,684,999 -$631,607 $1.11 15
2023 Q1 10,919,115 $10,918,005 -$44,044 $1.00 15
2022 Q4 11,067,830 $9,603,876 +$2,501 $0.87 18
2022 Q3 217,709 $282,000 -$1,721,326 $1.67 5
2022 Q2 14,969,473 $13,034,000 -$10,410,998 $0.87 26
2022 Q1 17,687,819 $53,391,000 -$622,344 $3.02 26
2021 Q4 16,966,777 $87,370,000 -$80,695,326 $5.15 28
2021 Q3 19,395,645 $467,497,000 +$8,028,087 $24.20 20
2021 Q2 19,072,268 $372,436,000 +$73,098,989 $19.53 16
2021 Q1 15,391,128 $284,643,000 +$284,643,000 $18.50 26